Indeed, pre-clinical [89–92] and clinical [93] studies show therapeutic efficacy in targeting AKT or co-targeting AKT plus the androgen axis/androgen receptor in castration-recurrent PC, yet ours is the first to use isogenic PC cell lines to address how PTEN and AKT isoforms affect metastatic signaling and progression. The gene discussed is PTEN; the disease is pachyonychia congenita.